rosiglitazone has been researched along with Parkinsonian Disorders in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carta, AR; Cassano, T; Giuffrida, A; Macheda, T; Martinez, AA; Morgese, MG; Paquette, MA; Pisanu, A; Seillier, A | 1 |
| Carta, AR; Casu, MA; Diana, A; Lecca, D; Mulas, G; Nevin, DK; Rossi, D; Sacchetti, G | 1 |
| Brenton, J; Cordeiro, MF; Davis, BM; De Groef, L; Guo, L; Malaguarnera, G; Nizari, S; Normando, EM; Pahlitzsch, M; Ravindran, N; Somavarapu, S; Turner, LA | 1 |
| Carboni, E; Carta, AR; Frau, L; Pisanu, A; Spiga, S; Wardas, J | 1 |
| Koh, HC; Lee, EY; Lee, JE; Park, JH; Shin, IC | 1 |
5 other study(ies) available for rosiglitazone and Parkinsonian Disorders
| Article | Year |
|---|---|
Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Dopamine; Dynorphins; Dyskinesia, Drug-Induced; Early Growth Response Protein 1; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphorylation; PPAR gamma; Rats, Sprague-Dawley; Rats, Wistar; Rosiglitazone; Thiazolidinediones | 2015 |
Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARγ agonist in vitro and in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Cells, Cultured; Cerebral Cortex; Disease Models, Animal; Encephalitis; Humans; Hydrogen Peroxide; Hypoglycemic Agents; Lipopolysaccharides; Male; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; Neurotoxins; NF-kappa B; Parkinsonian Disorders; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Thiobarbiturates; Tyrosine 3-Monooxygenase | 2015 |
The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson's disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain.
Topics: Animals; Antiparkinson Agents; Brain; Cell Survival; Cells, Cultured; Disease Progression; Drug Evaluation, Preclinical; Follow-Up Studies; Neuroprotective Agents; Parkinsonian Disorders; PPAR gamma; Rats; Retina; Rosiglitazone; Rotenone; Superior Sagittal Sinus; Thiazolidinediones; Tomography, Optical Coherence | 2016 |
Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model.
Topics: Animals; Disease Models, Animal; Disease Progression; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Microglia; Neuroprotective Agents; Parkinsonian Disorders; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2011 |
Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Topics: Animals; Basal Ganglia; Calcium-Binding Proteins; Cyclooxygenase 2; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Glial Fibrillary Acidic Protein; Injections, Intraperitoneal; Male; Microfilament Proteins; Nerve Degeneration; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Substantia Nigra; Thiazolidinediones; Time Factors; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase | 2012 |